Changsha Runlin Biotechnology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Changsha Runlin Biotechnology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 7 (Machinery) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include CARBORX. The owner is based in Changsha County, Hunan.

627, Bldg 18, Contemporary Plaza,

No. 288 Kaiyuan East Rd, Xingsha St,

Changsha County, Hunan 410100 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

CARBORX
CARBORX
Registered 2025

Trademark Classifications

Changsha Runlin Biotechnology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

7
Machinery (1 filing)

Machines and machine tools; motors and engines; machine coupling and transmission components

Frequently Asked Questions

How many trademarks does Changsha Runlin Biotechnology Co., Ltd. have?

Changsha Runlin Biotechnology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Changsha Runlin Biotechnology Co., Ltd. file in?

Changsha Runlin Biotechnology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 7 (Machinery). Class 7 covers machines and machine tools; motors and engines; machine coupling and transmission components.

What are Changsha Runlin Biotechnology Co., Ltd.'s most well-known trademarks?

Changsha Runlin Biotechnology Co., Ltd.'s registered trademark portfolio includes well-known marks such as CARBORX. These are among 1 currently registered trademark in the portfolio.

What is Changsha Runlin Biotechnology Co., Ltd.'s trademark registration success rate?

Changsha Runlin Biotechnology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.